How has been the historical performance of Sun Pharma.Inds.?

Revenue and Profit Growth

Sun Pharma.Inds. has seen its net sales rise significantly from ₹29,065.91 crores in March 2019 to ₹52,578.44 crores in March 2025, reflecting a robust compound growth over the six-year period. This growth underscores the company’s expanding market presence and product portfolio. Operating profit before depreciation and interest (PBDIT) excluding other income also increased from ₹6,307.59 crores in 2019 to ₹15,271.69 crores in 2025, indicating improved operational efficiency and cost management.

Including other income, operating profit rose to ₹17,236.73 crores in 2025 from ₹7,333.08 crores in 2019, more than doubling in six years. Profit before tax surged from ₹3,810.20 crores in 2019 to ₹13,752.13 crores in 2025, while profit after tax followed a similar trend, reaching ₹10,980.10 crores in 2025 compared to ₹3,209.32 crores in 2019. The consolidated net profit also showed a strong increase, climbing to ₹10,929.04 crores in 2025 from ₹2,665.42 crores in 2019.

Margins and Earnings Per Share

The company’s operating profit margin excluding other income improved steadily, reaching 29.35% in 2025 from 21.99% in 2019. Gross profit margin also expanded significantly, rising to 31.37% in 2025 from 19.39% in 2019, reflecting better cost control and pricing power. The profit after tax margin increased to 21.1% in 2025, nearly doubling from 11.19% in 2019, signalling enhanced profitability.

Earnings per share (EPS) followed a strong upward trend, climbing from ₹11.11 in 2019 to ₹45.55 in 2025, indicating substantial value creation for shareholders. The book value per share also rose from ₹188.66 in 2020 to ₹301 in 2025, highlighting growth in net asset value.

Balance Sheet and Financial Position

Sun Pharma.Inds. has strengthened its balance sheet over the years. Shareholder’s funds increased from ₹45,264.45 crores in 2020 to ₹72,218.02 crores in 2025, reflecting retained earnings and capital growth. Total assets grew from ₹65,077.17 crores in 2020 to ₹87,693.03 crores in 2025, supporting the company’s expanding operations.

Notably, the company has reduced its total debt substantially from ₹7,578.30 crores in 2020 to ₹1,869.63 crores in 2025, improving its leverage and financial stability. Net block of fixed assets remained relatively stable, indicating consistent investment in property, plant, and equipment. Capital work in progress and intangible assets under development have increased, signalling ongoing expansion and innovation efforts.

Cash Flow and Liquidity

Operating cash flow has shown a positive trend, with cash flow from operating activities rising to ₹14,072 crores in 2025 from ₹6,554 crores in 2020. Despite significant investing outflows reflecting capital expenditure and acquisitions, the company has managed financing activities prudently, resulting in a net positive cash inflow in recent years. Closing cash and cash equivalents increased to ₹10,268 crores in 2025 from ₹5,676 crores in 2020, underscoring strong liquidity.

Summary of Historical Performance

Over the six-year period ending March 2025, Sun Pharma.Inds. has exhibited strong and consistent growth across key financial parameters. Revenue and profits have more than doubled, margins have expanded, and earnings per share have increased substantially. The company’s balance sheet has strengthened with higher net worth and reduced debt, while cash flow generation has improved, supporting ongoing investments and shareholder returns.

This performance reflects Sun Pharma.Inds.’s successful execution of its business strategy, operational efficiencies, and market expansion. Investors can view the company’s historical financials as a solid foundation for future growth prospects in the pharmaceutical sector.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →